We Recently Purchased The Following:
Total Spent: $499.31; added $13.16 in forward dividends.
Gilead Sciences Inc (GILD)
Purchased 7 shares of GILD on 1/19/2017 at $71.33Total Spent: $499.31; added $13.16 in forward dividends.
We currently own shares of Gilead Sciences Inc (GILD) our family's dividend stocks portfolio. We initially purchased shares in GILD back on 9/9/2016 when we picked up 8 shares at $78.53. But with the current price near the 52-week low, we decided to add a few more shares of GILD to our family's dividend stocks portfolio. With our recent purchase, we now own 15 shares of GILD and have lowered our cost basis from $78.53 to $75.17. We also now receive $28.20 a year in dividends from GILD!
Based on our research, and the numerous articles relating to GILD, we find that GILD is a great value at current prices and a stock we certainly don't mind holding in our dividend stocks portfolio. Below are just a few links to Seeking Alpha articles on GILD:
- GILD is a core holding for 2017 - Trey Henninger
- Why Gilead is undervalued - Truth Investor
- How will Glead far in 2017 - Jonathon Weber
- Gilead is a fantastic stock to own at this price - Michael Wiggins De Oliveira
- Cure your portolio with Gilead - Blue Chip Investing
- Don't Trust Gilead's P/E Ratio - Erick Kobayashi-Solomon
Company Description
From Google Finance:
“Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.”
With our recent purchase of Gilead Sciences Inc (GILD), the estimated forward dividends for our family's dividend stocks portfolio grew another $13.16, putting our yearly dividends at approximately $2,831/year (excluding our Edwards Jones account) and $3,242/year (including our Edward Jones account).
Since we already own Gilead Sciences Inc (GILD), the total stocks held in our dividend stocks portfolios (WF and EJ Accounts) remains at 59 different dividend paying stocks/ETFs and also 5 companies that either don't pay a dividend our has currently suspended their dividends.
Our family's dividend stocks portfolio may be found
by clicking on the link below:
We also maintain an extensive list of stock analysis
that can be access through the link below:
We also just started a list of Recent Buys by other bloggers
that can be access through the link below:
HERE IS A QUICK FACT SHEET FOR THE STOCK I JUST PURCHASED:
Gilead Sciences Inc (GILD)
P/E: 6.59
Payout Ratio: 16%
Dividend Yield: 2.64%
1 consecutive years of dividend increases
Last Ex-dividend date: 12/13/2016
Dividend Yield: 2.64%
1 consecutive years of dividend increases
Last Ex-dividend date: 12/13/2016
Next Ex-dividend date: approx. 3/13/2017
Have paid a dividend since: 2015 (1 year)
Pays a dividend 4 times a year
Market Cap: 93.88 Billion
52-week high: $103.10
52-week low: $69.78
Purchased Price: $71.33
Have paid a dividend since: 2015 (1 year)
Pays a dividend 4 times a year
Market Cap: 93.88 Billion
52-week high: $103.10
52-week low: $69.78
Purchased Price: $71.33
What are your thoughts on of recent purchase?
What are you buying?
